Review of COVID-19 vaccine subtypes, efficacy and geographical distributions
As of 1 May 2021, there have been 152 661 445 Covid-19 cases with 3 202 256 deaths globally. This pandemic led to the race to discover a vaccine to achieve herd immunity and curtail the damaging effects of Covid-19. This study aims to discuss the most recent WHO-approved Covid-19 vaccine subtypes, t...
Gespeichert in:
| Veröffentlicht in: | Postgraduate medical journal 2022-05, Vol.98 (1159), p.389-394 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 394 |
|---|---|
| container_issue | 1159 |
| container_start_page | 389 |
| container_title | Postgraduate medical journal |
| container_volume | 98 |
| creator | Francis, Andre Ian Ghany, Saudah Gilkes, Tia Umakanthan, Srikanth |
| description | As of 1 May 2021, there have been 152 661 445 Covid-19 cases with 3 202 256 deaths globally. This pandemic led to the race to discover a vaccine to achieve herd immunity and curtail the damaging effects of Covid-19. This study aims to discuss the most recent WHO-approved Covid-19 vaccine subtypes, their status and geographical scheduled updates as of 4 May 2021. The keywords “Covid-19, Vaccines, Pfizer, BNT162b2, AstraZeneca, AZD1222, Moderna, mRNA-1273, Janssen, Ad26.COV2.S” were typed into PubMed. Thirty Two relevant PubMed articles were included in the study. The vaccines discussed are Pfizer/BNT162b2, Moderna Vaccine/mRNA1273, AstraZeneca/AZD122/ChAdOx1 n-CoV-19 and the Janssen vaccines/Ad26.COV2.S, as well as their platforms, trials, limitations and geographical distributions. As of 16 May 2021, the number of countries that have approved the use of the following vaccines is Pfizer in 85, Moderna in 46, Oxford/AstraZeneca in 101, and Janssen in 41. |
| doi_str_mv | 10.1136/postgradmedj-2021-140654 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2802422635</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2656885994</sourcerecordid><originalsourceid>FETCH-LOGICAL-b482t-7082809b2a0c49903f0028a7b1e4f47881f3aec85b4d9e0a0c1748662ba33c793</originalsourceid><addsrcrecordid>eNqVkFtLwzAYhoMobh7-ggS88cJqTk2TS5mnwWAg6m1I0nS2dG1t2sn-vRmdU7wRrwJfnvf9Ph4AIEZXGFN-3dS-W7Q6Xbq0iAgiOMIM8ZjtgTFmXEYoifk-GCNESRSzhI7AkfcFQpgmDB-CEWWUExHzMZg9uVXuPmCdwcn8dXobYQlX2tq8ctD3pls3zl9Cl2W51XYNdZXChavD7uYtTEqY5r5rc9N3eV35E3CQ6dK70-17DF7u754nj9Fs_jCd3MwiwwTpogQJIpA0RCPLpEQ0Q4gInRjsWMYSIXBGtbMiNiyVDgUKJ0xwToym1CaSHoOLobdp6_fe-U4tc29dWerK1b1XoZ0wQjiNA3r-Cy3qvq3CdYrwmAsRS8kCJQbKtrX3rctU0-ZL3a4VRmpjXP00rjbG1WA8RM-2C3oTPnfBL8UBoANglsV_atl3anfyn7FPqiGgDQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656885994</pqid></control><display><type>article</type><title>Review of COVID-19 vaccine subtypes, efficacy and geographical distributions</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Francis, Andre Ian ; Ghany, Saudah ; Gilkes, Tia ; Umakanthan, Srikanth</creator><creatorcontrib>Francis, Andre Ian ; Ghany, Saudah ; Gilkes, Tia ; Umakanthan, Srikanth</creatorcontrib><description>As of 1 May 2021, there have been 152 661 445 Covid-19 cases with 3 202 256 deaths globally. This pandemic led to the race to discover a vaccine to achieve herd immunity and curtail the damaging effects of Covid-19. This study aims to discuss the most recent WHO-approved Covid-19 vaccine subtypes, their status and geographical scheduled updates as of 4 May 2021. The keywords “Covid-19, Vaccines, Pfizer, BNT162b2, AstraZeneca, AZD1222, Moderna, mRNA-1273, Janssen, Ad26.COV2.S” were typed into PubMed. Thirty Two relevant PubMed articles were included in the study. The vaccines discussed are Pfizer/BNT162b2, Moderna Vaccine/mRNA1273, AstraZeneca/AZD122/ChAdOx1 n-CoV-19 and the Janssen vaccines/Ad26.COV2.S, as well as their platforms, trials, limitations and geographical distributions. As of 16 May 2021, the number of countries that have approved the use of the following vaccines is Pfizer in 85, Moderna in 46, Oxford/AstraZeneca in 101, and Janssen in 41.</description><identifier>ISSN: 0032-5473</identifier><identifier>EISSN: 1469-0756</identifier><identifier>DOI: 10.1136/postgradmedj-2021-140654</identifier><identifier>PMID: 34362856</identifier><language>eng</language><publisher>England: The Fellowship of Postgraduate Medicine</publisher><subject>Ad26COVS1 ; Adenoviruses ; Antibodies ; BNT162 Vaccine ; ChAdOx1 nCoV-19 ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 Vaccines ; Disease transmission ; Epidemics ; Humans ; Infections ; Influenza ; Monkeys & apes ; Nanoparticles ; Pandemics ; Proteins ; Review ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccines ; Vectors (Biology) ; virology</subject><ispartof>Postgraduate medical journal, 2022-05, Vol.98 (1159), p.389-394</ispartof><rights>Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained. https://bmj.com/coronavirus/usage</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b482t-7082809b2a0c49903f0028a7b1e4f47881f3aec85b4d9e0a0c1748662ba33c793</citedby><cites>FETCH-LOGICAL-b482t-7082809b2a0c49903f0028a7b1e4f47881f3aec85b4d9e0a0c1748662ba33c793</cites><orcidid>0000-0002-7456-8665</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34362856$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Francis, Andre Ian</creatorcontrib><creatorcontrib>Ghany, Saudah</creatorcontrib><creatorcontrib>Gilkes, Tia</creatorcontrib><creatorcontrib>Umakanthan, Srikanth</creatorcontrib><title>Review of COVID-19 vaccine subtypes, efficacy and geographical distributions</title><title>Postgraduate medical journal</title><addtitle>Postgrad Med J</addtitle><addtitle>Postgrad Med J</addtitle><description>As of 1 May 2021, there have been 152 661 445 Covid-19 cases with 3 202 256 deaths globally. This pandemic led to the race to discover a vaccine to achieve herd immunity and curtail the damaging effects of Covid-19. This study aims to discuss the most recent WHO-approved Covid-19 vaccine subtypes, their status and geographical scheduled updates as of 4 May 2021. The keywords “Covid-19, Vaccines, Pfizer, BNT162b2, AstraZeneca, AZD1222, Moderna, mRNA-1273, Janssen, Ad26.COV2.S” were typed into PubMed. Thirty Two relevant PubMed articles were included in the study. The vaccines discussed are Pfizer/BNT162b2, Moderna Vaccine/mRNA1273, AstraZeneca/AZD122/ChAdOx1 n-CoV-19 and the Janssen vaccines/Ad26.COV2.S, as well as their platforms, trials, limitations and geographical distributions. As of 16 May 2021, the number of countries that have approved the use of the following vaccines is Pfizer in 85, Moderna in 46, Oxford/AstraZeneca in 101, and Janssen in 41.</description><subject>Ad26COVS1</subject><subject>Adenoviruses</subject><subject>Antibodies</subject><subject>BNT162 Vaccine</subject><subject>ChAdOx1 nCoV-19</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Vaccines</subject><subject>Disease transmission</subject><subject>Epidemics</subject><subject>Humans</subject><subject>Infections</subject><subject>Influenza</subject><subject>Monkeys & apes</subject><subject>Nanoparticles</subject><subject>Pandemics</subject><subject>Proteins</subject><subject>Review</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccines</subject><subject>Vectors (Biology)</subject><subject>virology</subject><issn>0032-5473</issn><issn>1469-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqVkFtLwzAYhoMobh7-ggS88cJqTk2TS5mnwWAg6m1I0nS2dG1t2sn-vRmdU7wRrwJfnvf9Ph4AIEZXGFN-3dS-W7Q6Xbq0iAgiOMIM8ZjtgTFmXEYoifk-GCNESRSzhI7AkfcFQpgmDB-CEWWUExHzMZg9uVXuPmCdwcn8dXobYQlX2tq8ctD3pls3zl9Cl2W51XYNdZXChavD7uYtTEqY5r5rc9N3eV35E3CQ6dK70-17DF7u754nj9Fs_jCd3MwiwwTpogQJIpA0RCPLpEQ0Q4gInRjsWMYSIXBGtbMiNiyVDgUKJ0xwToym1CaSHoOLobdp6_fe-U4tc29dWerK1b1XoZ0wQjiNA3r-Cy3qvq3CdYrwmAsRS8kCJQbKtrX3rctU0-ZL3a4VRmpjXP00rjbG1WA8RM-2C3oTPnfBL8UBoANglsV_atl3anfyn7FPqiGgDQ</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Francis, Andre Ian</creator><creator>Ghany, Saudah</creator><creator>Gilkes, Tia</creator><creator>Umakanthan, Srikanth</creator><general>The Fellowship of Postgraduate Medicine</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7456-8665</orcidid></search><sort><creationdate>20220501</creationdate><title>Review of COVID-19 vaccine subtypes, efficacy and geographical distributions</title><author>Francis, Andre Ian ; Ghany, Saudah ; Gilkes, Tia ; Umakanthan, Srikanth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b482t-7082809b2a0c49903f0028a7b1e4f47881f3aec85b4d9e0a0c1748662ba33c793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Ad26COVS1</topic><topic>Adenoviruses</topic><topic>Antibodies</topic><topic>BNT162 Vaccine</topic><topic>ChAdOx1 nCoV-19</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Vaccines</topic><topic>Disease transmission</topic><topic>Epidemics</topic><topic>Humans</topic><topic>Infections</topic><topic>Influenza</topic><topic>Monkeys & apes</topic><topic>Nanoparticles</topic><topic>Pandemics</topic><topic>Proteins</topic><topic>Review</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccines</topic><topic>Vectors (Biology)</topic><topic>virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Francis, Andre Ian</creatorcontrib><creatorcontrib>Ghany, Saudah</creatorcontrib><creatorcontrib>Gilkes, Tia</creatorcontrib><creatorcontrib>Umakanthan, Srikanth</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Postgraduate medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Francis, Andre Ian</au><au>Ghany, Saudah</au><au>Gilkes, Tia</au><au>Umakanthan, Srikanth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Review of COVID-19 vaccine subtypes, efficacy and geographical distributions</atitle><jtitle>Postgraduate medical journal</jtitle><stitle>Postgrad Med J</stitle><addtitle>Postgrad Med J</addtitle><date>2022-05-01</date><risdate>2022</risdate><volume>98</volume><issue>1159</issue><spage>389</spage><epage>394</epage><pages>389-394</pages><issn>0032-5473</issn><eissn>1469-0756</eissn><abstract>As of 1 May 2021, there have been 152 661 445 Covid-19 cases with 3 202 256 deaths globally. This pandemic led to the race to discover a vaccine to achieve herd immunity and curtail the damaging effects of Covid-19. This study aims to discuss the most recent WHO-approved Covid-19 vaccine subtypes, their status and geographical scheduled updates as of 4 May 2021. The keywords “Covid-19, Vaccines, Pfizer, BNT162b2, AstraZeneca, AZD1222, Moderna, mRNA-1273, Janssen, Ad26.COV2.S” were typed into PubMed. Thirty Two relevant PubMed articles were included in the study. The vaccines discussed are Pfizer/BNT162b2, Moderna Vaccine/mRNA1273, AstraZeneca/AZD122/ChAdOx1 n-CoV-19 and the Janssen vaccines/Ad26.COV2.S, as well as their platforms, trials, limitations and geographical distributions. As of 16 May 2021, the number of countries that have approved the use of the following vaccines is Pfizer in 85, Moderna in 46, Oxford/AstraZeneca in 101, and Janssen in 41.</abstract><cop>England</cop><pub>The Fellowship of Postgraduate Medicine</pub><pmid>34362856</pmid><doi>10.1136/postgradmedj-2021-140654</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-7456-8665</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0032-5473 |
| ispartof | Postgraduate medical journal, 2022-05, Vol.98 (1159), p.389-394 |
| issn | 0032-5473 1469-0756 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2802422635 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Ad26COVS1 Adenoviruses Antibodies BNT162 Vaccine ChAdOx1 nCoV-19 Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Vaccines Disease transmission Epidemics Humans Infections Influenza Monkeys & apes Nanoparticles Pandemics Proteins Review SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccines Vectors (Biology) virology |
| title | Review of COVID-19 vaccine subtypes, efficacy and geographical distributions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T10%3A07%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Review%20of%20COVID-19%20vaccine%20subtypes,%20efficacy%20and%20geographical%20distributions&rft.jtitle=Postgraduate%20medical%20journal&rft.au=Francis,%20Andre%20Ian&rft.date=2022-05-01&rft.volume=98&rft.issue=1159&rft.spage=389&rft.epage=394&rft.pages=389-394&rft.issn=0032-5473&rft.eissn=1469-0756&rft_id=info:doi/10.1136/postgradmedj-2021-140654&rft_dat=%3Cproquest_cross%3E2656885994%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2656885994&rft_id=info:pmid/34362856&rfr_iscdi=true |